IGFBP6 and chronic myelogenous leukemia, BCR-ABL1 positive: Insulin-like Growth Factor Binding Protein-6 (IGFBP-6) is expressed during tumor development, and is involved in immune-escape and inflammation as well, providing a potential additional target for CML therapy.